Clinical Trial Demonstrates Positive Top-Line Results in Reducing the Risk for Cardiovascular Death or Hospitalisation due to Heart Failure
Dubai, United Arab Emirates – August 6th , 2020: Boehringer Ingelheim – one of the world’s leading pharmaceutical companies has announced positive top-line results from the EMPEROR-Reduced Phase III trial in adults with chronic heart failure with reduced ejection fraction. The trial met its primary endpoint, demonstrating superiority empagliflozin (10mg) versus placebo on top of standard of care, in reducing the risk for cardiovascular death or hospitalisation due to heart failure.
Many Middle Eastern countries have observed increases in the prevalence of risk factors for heart failure, which is seen to develop in their populations at least 10 years earlier than in Western counterpart populations. The risk factors include diabetes mellitus, obesity, and hypertension. Heart failure with reduced ejection fraction occurs when the heart muscle does not contract effectively and pumps out less blood to the body compared to a normally functioning heart. Symptoms associated with heart failure include breathlessness and fatigue, which can severely impact upon quality of life. There remains a high unmet need in the treatment of heart failure, as approximately 50 percent of all those diagnosed with the condition die within five years.
The EMPEROR-Reduced clinical trials form part of the EMPOWER clinical programme, one of the broadest, most comprehensive trials of any SGLT2 inhibitor, exploring the impact of treatments across cardio-renal-metabolic conditions. Building on findings from EMPA-REG OUTCOME®, these positive results demonstrate that empagliflozin has the potential to fill unmet therapeutic needs for people with this highly prevalent condition.
Full results from the EMPEROR-Reduced trial will be presented in a hot line session at the European Society of Cardiology (ESC) congress 2020, which is being held 29 August. A second trial, EMPEROR-Preserved, the results of which are expected in 2021, will explore the effect of empagliflozin on cardiovascular death and hospitalisation for heart failure in adults with heart failure with preserved ejection fraction – an area of high unmet need as there are currently no treatment options available for people with this form of heart failure.
Notes to the editor:
About Boehringer Ingelheim
Making new and better medicines for humans and animals is at the heart of what we do. Our mission is to create breakthrough therapies that change lives. Since its founding in 1885, Boehringer Ingelheim is independent and family-owned. We have the freedom to pursue our long-term vision, looking ahead to identify the health challenges of the future and targeting those areas of need where we can do the most good.
As a world-leading, research-driven pharmaceutical company, our more than 51,000 employees create value through innovation daily for our three business areas: Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. In 2019, Boehringer Ingelheim achieved net sales of 19 billion euros. Our significant investment of almost 3.5 billion euros in R&D drives innovation, enabling the next generation of medicines that save lives and improves quality of life.
We realise more scientific opportunities by embracing the power of partnership and diversity of experts across the life-science community. By working together, we accelerate the delivery of the next medical breakthrough that will transform the lives of patients now, and in generations to come.